Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avricore Health Inc. V.AVCR

Alternate Symbol(s):  AVCRF

Avricore Health Inc. is committed to becoming a health innovator and applying technologies at the forefront of science to core health issues at the community pharmacy level. The Company’s goal is to empower consumers, patients and pharmacists with innovative technology, products, services and information to monitor and optimize health.


TSXV:AVCR - Post by User

Bullboard Posts
Comment by kingposton Jan 19, 2015 2:55pm
162 Views
Post# 23336120

RE:$170 billion value in patents are expiring in 2015......if

RE:$170 billion value in patents are expiring in 2015......if excellent market data naimarantz..

naimarantz wrote: the value in generics is only 20% that's a $34b market NPH has a license to tap into. How many $10m companies are out there that have licensed access to this market, approval to sell over 30 of Canada's best selling generics and a license to bring patented drugs into Canada?


I am thinking much higher than 20% at least in the first couple years and even behond:

-firstly the first generics to market gets 6 monthes exclusivity and then with  other factors it often takes up to a couple years for the second generic to come out (prices stay at approx 70% for these first ones),

-secondly, some of these are "specialty geberics" like ones that include hardware such as a deliver device like an inhaler or different delivery method and these ones prices stay much higher and possibly the same as the brand..

India is the main source but china. Ireland and the USA are other souces...we could build a huge company off of Indian supply. but management smartly has already made a presence in China and Canada for additional manufacturing ....China will have a huge growth going forward because they have the population needing generics and they are good at "knowledge industries"..

To me it looks like we are strong with Indian manufacturing supply connections, what I am keeping an eye on as  is seeing whether or not we need to beef up our deal making skill package that can be focused on US and European deal making.... to run parralel to the Indian side..




Bullboard Posts